141 related articles for article (PubMed ID: 23707991)
1. Newer therapeutic strategies to alter high-density lipoprotein level and function.
Bosch N; Frishman WH
Cardiol Rev; 2014; 22(1):17-24. PubMed ID: 23707991
[TBL] [Abstract][Full Text] [Related]
2. Emerging therapeutic strategies to enhance HDL function.
Redondo S; Martínez-González J; Urraca C; Tejerina T
Lipids Health Dis; 2011 Oct; 10():175. PubMed ID: 21985435
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of high-density lipoprotein in the prevention of cardiovascular disease.
Brousseau ME
Drug Discov Today; 2005 Aug; 10(16):1095-101. PubMed ID: 16182194
[TBL] [Abstract][Full Text] [Related]
4. [New trends in lipidology: the increasing role of HDL-cholesterol].
Paragh G; Harangi M; László M
Orv Hetil; 2008 Jul; 149(30):1395-404. PubMed ID: 18621598
[TBL] [Abstract][Full Text] [Related]
5. Novel targets that affect high-density lipoprotein metabolism: the next frontier.
Davidson MH; Rosenson RS
Am J Cardiol; 2009 Nov; 104(10 Suppl):52E-7E. PubMed ID: 19895945
[TBL] [Abstract][Full Text] [Related]
6. Reverse cholesterol transport in type 2 diabetes mellitus.
Tan KC
Diabetes Obes Metab; 2009 Jun; 11(6):534-43. PubMed ID: 19175378
[TBL] [Abstract][Full Text] [Related]
7. [High-density lipoprotein (HDL) and cholesteryl ester transfer protein (CETP): role in lipid metabolism and clinical meaning].
Kleber ME; Grammer TB; März W
MMW Fortschr Med; 2010 Jul; 152 Suppl 2():47-55. PubMed ID: 21591319
[TBL] [Abstract][Full Text] [Related]
8. High-density lipoproteins: multifunctional vanguards of the cardiovascular system.
Marcil M; O'Connell B; Krimbou L; Genest J
Expert Rev Cardiovasc Ther; 2004 May; 2(3):417-30. PubMed ID: 15151487
[TBL] [Abstract][Full Text] [Related]
9. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation).
Nicholls SJ; Tuzcu EM; Brennan DM; Tardif JC; Nissen SE
Circulation; 2008 Dec; 118(24):2506-14. PubMed ID: 19029466
[TBL] [Abstract][Full Text] [Related]
10. Treatment options for low high-density lipoproteins.
Hafiane A; Kellett S; Genest J
Curr Opin Endocrinol Diabetes Obes; 2014 Apr; 21(2):134-9. PubMed ID: 24535232
[TBL] [Abstract][Full Text] [Related]
11. High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm.
Tuteja S; Rader DJ
Clin Pharmacol Ther; 2014 Jul; 96(1):48-56. PubMed ID: 24713591
[TBL] [Abstract][Full Text] [Related]
12. High-density lipoprotein and coronary heart disease: current and future therapies.
Natarajan P; Ray KK; Cannon CP
J Am Coll Cardiol; 2010 Mar; 55(13):1283-99. PubMed ID: 20338488
[TBL] [Abstract][Full Text] [Related]
13. High-Density Lipoprotein Subfractions and Cholesterol Efflux Capacities After Infusion of MDCO-216 (Apolipoprotein A-IMilano/Palmitoyl-Oleoyl-Phosphatidylcholine) in Healthy Volunteers and Stable Coronary Artery Disease Patients.
Kempen HJ; Asztalos BF; Moerland M; Jeyarajah E; Otvos J; Kallend DG; Bellibas SE; Wijngaard PL
Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):736-42. PubMed ID: 26916733
[TBL] [Abstract][Full Text] [Related]
14. Refocusing on use of cholesteryl ester transfer protein inhibitors.
Kastelein JJ
Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853
[TBL] [Abstract][Full Text] [Related]
15. Upregulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination with the LDL-lowering drug berberine in dyslipidemic hamsters.
Briand F; Thieblemont Q; Muzotte E; Sulpice T
Arterioscler Thromb Vasc Biol; 2013 Jan; 33(1):13-23. PubMed ID: 23139291
[TBL] [Abstract][Full Text] [Related]
16. High-density lipoprotein therapeutics and cardiovascular prevention.
Fazio S; Linton MF
J Clin Lipidol; 2010; 4(5):411-9. PubMed ID: 21122685
[TBL] [Abstract][Full Text] [Related]
17. A selective peroxisome proliferator-activated receptor δ agonist PYPEP suppresses atherosclerosis in association with improvement of the serum lipoprotein profiles in human apolipoprotein B100 and cholesteryl ester transfer protein double transgenic mice.
Naya N; Fukao K; Nakamura A; Hamada T; Sugimoto M; Kojima M; Yoshimura N; Uwabe K; Imagawa K; Nomura K; Hara S; Nakano T; Iwasaki T; Shinosaki T; Hanasaki K
Metabolism; 2016 Jan; 65(1):16-25. PubMed ID: 26683793
[TBL] [Abstract][Full Text] [Related]
18. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
19. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
20. Targeting high-density lipoproteins: update on a promising therapy.
Verdier C; Martinez LO; Ferrières J; Elbaz M; Genoux A; Perret B
Arch Cardiovasc Dis; 2013 Nov; 106(11):601-11. PubMed ID: 24074699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
